WUXI BIOLOGICS (CAYMAN) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.46 HKD | +3.06% |
|
+1.78% | -61.28% |
| Jun. 27 | Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14 | MT |
| Jun. 19 | Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment | MT |
| Sales 2024 * | 18.13B 2.5B 19.51B | Sales 2025 * | 21.07B 2.9B 22.67B | Capitalization | 44.18B 6.09B 47.54B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.84B 530M 4.14B | Net income 2025 * | 4.63B 638M 4.98B | EV / Sales 2024 * | 2.04 x |
| Net cash position 2024 * | 7.25B 999M 7.8B | Net cash position 2025 * | 8.19B 1.13B 8.81B | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
11.9
x | P/E ratio 2025 * |
9.9
x | Employees | 12,740 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85% |
More Fundamentals
* Assessed data
More news
Latest transcript on WuXi Biologics (Cayman) Inc.
More recommendations
More press releases
More news
| 1 day | +3.06% | ||
| 1 week | +1.78% | ||
| Current month | -0.69% | ||
| 1 month | -6.68% | ||
| 3 months | -17.55% | ||
| 6 months | -61.15% | ||
| Current year | -61.28% |
1 week
10.56
11.56
1 month
10.5612.26
Current year
10.5633.40
1 year
10.5652.45
3 years
10.56142.90
5 years
10.56148.00
10 years
8.33148.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 11-05-31 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 21-08-22 |
Ji Jie Gu
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 23-05-05 |
William Keller
BRD | Director/Board Member | 75 | 17-05-16 |
Ge Li
CHM | Chairman | 56 | 10-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.62% | 1 M€ | -22.25% | - | |
| 4.23% | 2 M€ | +2.06% | - | |
| 3.58% | 1 M€ | -9.86% | - | |
| 2.95% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 11.46 | +3.06% | 41,423,820 |
| 24-07-11 | 11.12 | +4.32% | 39,504,020 |
| 24-07-10 | 10.66 | -1.66% | 26,726,280 |
| 24-07-09 | 10.84 | +0.56% | 28,854,900 |
| 24-07-08 | 10.78 | -4.26% | 50,467,620 |
Delayed Quote Hong Kong S.E., July 12, 2024 at 04:08 am EDT
More quotes
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
10.64
CNY
Average target price
20.93
CNY
Spread / Average Target
+96.70%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -61.28% | 6.09B | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- 2269 Stock
